Literature DB >> 22160611

Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment.

Eitan Nahshoni1, Pavel Golubchik, Jonathan Glazer, Jonathan Sever, Boris Strasberg, Shula Imbar, Gal Shoval, Abraham Weizman, Gil Zalsman.   

Abstract

Reports on sudden cardiac death (SCD) of children and adolescents treated with stimulant agents have raised concerns regarding the need for cardiovascular monitoring and risk stratification schedules. Cardiac ventricular late potentials (LPs) represent delayed ventricular activation that might predispose to fatal ventricular arrhythmias and SCD in cardiac patients. LPs have not previously been measured in children with attention deficit/hyperactivity disorder (ADHD). LPs were measured in 18 physically healthy ADHD children (5 girls and 13 boys, age 11.9 ± 2.5 years, treatment duration 2.6 ± 1.9 years) before and 2 h after oral methylphenidate administration. No significant changes were detected and LPs were found to be within normal ranges. In conclusion, this preliminary small-scale study suggests that methylphenidate in physically healthy children with ADHD was not associated with cardiac ventricular LPs, suggesting the safety of the agent in this age group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160611     DOI: 10.1007/s00787-011-0233-x

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  21 in total

Review 1.  Electrocardiographic arrhythmia risk testing.

Authors:  Gregory Engel; James G Beckerman; Victor F Froelicher; Takuya Yamazaki; Henry A Chen; Kelly Richardson; Ryan J McAuley; Euan A Ashley; Sung Chun; Paul J Wang
Journal:  Curr Probl Cardiol       Date:  2004-07       Impact factor: 5.200

2.  Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography. A statement by a Task Force Committee of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology.

Authors:  G Breithardt; M E Cain; N el-Sherif; N C Flowers; V Hombach; M Janse; M B Simson; G Steinbeck
Journal:  Circulation       Date:  1991-04       Impact factor: 29.690

Review 3.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

4.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

5.  Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.

Authors:  Richard Donner; M Alex Michaels; Paul J Ambrosini
Journal:  Biol Psychiatry       Date:  2006-08-08       Impact factor: 13.382

6.  Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings.

Authors:  R T Brown; W S Freeman; J M Perrin; M T Stein; R W Amler; H M Feldman; K Pierce; M L Wolraich
Journal:  Pediatrics       Date:  2001-03       Impact factor: 7.124

7.  Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.

Authors:  Robert L Findling; Joseph Biederman; Timothy E Wilens; Thomas J Spencer; James J McGough; Frank A Lopez; Simon J Tulloch
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

8.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Authors:  Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

9.  Early repolarization in young children with attention-deficit/hyperactivity disorder versus normal controls: a retrospective preliminary chart review study.

Authors:  Eitan Nahshoni; Samuel Sclarovsky; Sara Spitzer; Gil Zalsman; Boris Strasberg; Abraham Weizman
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576

10.  European guidelines on managing adverse effects of medication for ADHD.

Authors:  J Graham; T Banaschewski; J Buitelaar; D Coghill; M Danckaerts; R W Dittmann; M Döpfner; R Hamilton; C Hollis; M Holtmann; M Hulpke-Wette; M Lecendreux; E Rosenthal; A Rothenberger; P Santosh; J Sergeant; E Simonoff; E Sonuga-Barke; I C K Wong; A Zuddas; H-C Steinhausen; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-11-03       Impact factor: 4.785

View more
  2 in total

Review 1.  Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.

Authors:  Jose Martinez-Raga; Amparo Ferreros; Carlos Knecht; Raquel de Alvaro; Eloisa Carabal
Journal:  Ther Adv Drug Saf       Date:  2016-11-29

Review 2.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.